BACE1 and Alzheimer disease: Additionally, all the compounds showed the ability to interfere with amyloid fibril formation Hence these compounds might act as potential starting compounds to target BACE1 inhibition as well as antiamyloidogenicity and therefore be used in AD therapeutics.